{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-25-000011","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.420510+00:00","generated_at":"2026-05-26T05:34:45.770691+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Supernus approves executive salary increases and equity awards for 2025","bullets":["CEO Jack Khattar base salary raised to $1,036,000; 2024 bonus $826,254; awarded 331,660 options and 198,996 PSUs.","CFO Timothy Dec base salary raised to $504,900; 2024 bonus $229,160; awarded 40,000 options, 4,500 RSUs, 5,000 PSUs.","Three other execs (Bhatt, Rubin, Mottola) got salary increases, 2024 bonuses, and similar equity grants.","All 2025 bonus targets unchanged from 2024; salary increases effective Jan 1, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-25-000011","json":"https://secwatch.observer/filing/0001356576-25-000011.json","markdown":"https://secwatch.observer/filing/0001356576-25-000011.md","text":"https://secwatch.observer/filing/0001356576-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000011/0001356576-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000011/supn-20250224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T05:34:45.770691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}